Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Share News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: UBS Initiates Restaurant Group At Buy

Fri, 18th Dec 2015 09:39

LONDON (Alliance News) - The following shares received analyst recommendations Friday morning:
----------
FTSE 100
----------
Societe Generale Cuts Glencore Price Target To 100p From 130p, Keeps Buy
----------
EXANE BNP CUTS MARKS & SPENCER PRICE TARGET TO 580 (620) PENCE - 'OUTPERFORM'
----------
EXANE BNP RAISES DIXONS CARPHONE PRICE TARGET TO 560 (510) PENCE - 'OUTPERFORM'
----------
UBS CUTS RIO TINTO PRICE TARGET TO 2600 (2700) PENCE - 'BUY'
----------
UBS CUTS ANTOFAGASTA PRICE TARGET TO 450 (510) PENCE - 'NEUTRAL'
----------
GOLDMAN CUTS RIO TINTO PRICE TARGET TO 1700 (1825) PENCE - 'SELL'
----------
GOLDMAN CUTS BHP BILLITON PRICE TARGET TO 750 (925) PENCE - 'NEUTRAL'
----------
GOLDMAN CUTS ANGLO AMERICAN PRICE TARGET TO 250 (280) PENCE - 'SELL'
----------
FTSE 250
----------
UBS INITIATES RESTAURANT GROUP WITH 'BUY' - TARGET 860 PENCE
----------
Numis Cuts Elementis Target To 253p From 271p, Keeps Add
----------
EXANE BNP CUTS ELEMENTIS PRICE TARGET TO 220 (250) PENCE - 'NEUTRAL'
----------
JPMORGAN CUTS ELEMENTIS PRICE TARGET TO 215 (255) PENCE - 'NEUTRAL'
----------
EXANE BNP CUTS N BROWN PRICE TARGET TO 260 (280) PENCE - 'UNDERPERFORM'
----------
EXANE BNP CUTS HOME RETAIL PRICE TARGET TO 80 (100) PENCE - 'UNDERPERFORM'
----------
N+1 Singer Upgrades Bodycote To Buy From Hold, Price Target At 635p
----------
UBS CUTS VEDANTA PRICE TARGET TO 330 (400) PENCE - 'NEUTRAL'
----------
UBS CUTS ACACIA MINING PRICE TARGET TO 275 (300) PENCE - 'BUY'
----------
UBS CUTS BOVIS HOMES PRICE TARGET TO 1290 (1450) PENCE - 'BUY'
----------
BARCLAYS CUTS VICTREX TO 'EQUAL WEIGHT' ('OVERWEIGHT') - TARGET 2100 (2300) PENCE
----------
BERENBERG RAISES NORTHGATE TO 'HOLD' ('SELL') - TARGET 400 (455) PENCE
----------
MAIN MARKET AND AIM
----------
Liberum Cuts PureTech Health Target To 194p From 199p, Keeps Buy
----------
Cantor Fitzgerald Cuts Bonmarche Holdings Target To 230p From 350p
----------
Cantor Fitzgerald Downgrades Bonmarche Holdings To Hold From Buy
----------
Panmure Ups Midatech Pharma Target To 476p From 417p, Keeps Buy
----------
PANMURE CUTS FENNER PRICE TARGET TO 100 (125) PENCE - 'SELL'
----------
EXANE BNP CUTS SIGNET GROUP PRICE TARGET TO 9400 (10000) PENCE - 'OUTPERFORM'
----------
EXANE BNP RAISES ASOS PRICE TARGET TO 4400 (4100) PENCE - 'OUTPERFORM'
----------
EXANE BNP CUTS IMAGINATION TECHNOLOGIES PRICE TARGET TO 95 (130) PENCE - 'UNDERPERFORM'
----------
DEUTSCHE BANK CUTS IMAGINATION TECHNOLOGIES PRICE TARGET TO 105 (215) PENCE - 'HOLD'
----------
HSBC CUTS STHREE PRICE TARGET TO 405 (425) PENCE - 'BUY'
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
24 Feb 2020 16:02

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
8 Jan 2020 15:51

Midatech shares surge on success of latest MTD201 study

(Sharecast News) - Biotechnology research and development company Midatech Pharma announced positive headline results from 'study 102' on Wednesday, which it said met its primary endpoints to confirm similar pharmacokinetics and bioavailability of octreotide for subcutaneous and intramuscular routes of administration.

Read more
8 Jan 2020 09:51

Positive Headline Reading For Latest Midatech MTD201 Study

Positive Headline Reading For Latest Midatech MTD201 Study

Read more
17 Dec 2019 16:39

Midatech Pharma American Shares Risk To Be Delisted Amid Low Bid Price

Midatech Pharma American Shares Risk To Be Delisted Amid Low Bid Price

Read more
5 Dec 2019 15:59

Midatech Pharma Gets EU Grant For Brain Cancer Drug

Midatech Pharma Gets EU Grant For Brain Cancer Drug

Read more
4 Nov 2019 18:47

Armistice Capital Takes Almost 10% Interest In Midatech Pharma

Armistice Capital Takes Almost 10% Interest In Midatech Pharma

Read more
24 Oct 2019 11:50

Midatech Pharma Childhood Cancer Drug Given FDA Orphan Designation

Midatech Pharma Childhood Cancer Drug Given FDA Orphan Designation

Read more
23 Oct 2019 09:29

Midatech Pharma Inks USD3.0 Million Registered Direct Offering Deal

Midatech Pharma Inks USD3.0 Million Registered Direct Offering Deal

Read more
8 Oct 2019 11:34

Midatech Doses First Patients In MTD201 Administration Method Study

Midatech Doses First Patients In MTD201 Administration Method Study

Read more
8 Oct 2019 09:24

Midatech Pharma doses first volunteers in acromegaly treatment study

(Sharecast News) - Midatech Pharma on Tuesday announced that its MTD201 Phase 1 study for the treatment of acromegaly and neuroendocrine tumours has commenced.

Read more
7 Oct 2019 15:45

DIRECTOR DEALINGS: Midatech Pharma CFO Buys GBP30,000 In Shares

DIRECTOR DEALINGS: Midatech Pharma CFO Buys GBP30,000 In Shares

Read more
3 Oct 2019 15:40

DIRECTOR DEALINGS: Midatech Pharma CFO Stephen Stamp Buys Shares

DIRECTOR DEALINGS: Midatech Pharma CFO Stephen Stamp Buys Shares

Read more
30 Sep 2019 19:06

Midatech Pharma Slims Interim Loss As Cancer Treatments Progress

Midatech Pharma Slims Interim Loss As Cancer Treatments Progress

Read more
24 Sep 2019 14:32

Midatech Pharma Applies To US Regulator For Share Issue Authority

Midatech Pharma Applies To US Regulator For Share Issue Authority

Read more
20 Sep 2019 15:43

Midatech Pharma gets approval for next MTD201 study

(Sharecast News) - Biotechnology company Midatech Pharma has received approval to commence a phase 1 study on MTD201, which it is developing for the treatment of acromegaly and neuroendocrine tumours (NET).

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.